Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
NCT ID: NCT00898781
Last Updated: 2011-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
80 participants
OBSERVATIONAL
2007-11-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at the number of circulating cancer cells in patients with metastatic breast cancer, ovarian cancer, colon cancer, or pancreatic cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC
NCT02436772
Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease
NCT02781025
Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.
NCT00974610
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
NCT05530759
Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
NCT06217874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To assess frequency of circulating tumor cells (CTCs) in patients with metastatic ovarian, breast, pancreatic, and colon cancers.
* To assess the variability in number of CTCs between patients with the same tumor type.
* To correlate the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers.
OUTLINE: Blood samples are collected before treatment and analyzed using molecular detection techniques to detect circulating cancer cells. Samples are assessed by immunofluorescence for markers of proliferation and survival (e.g., EGFR, phosphorylated EGFR, AKT, phosphorylated AKT, cytokeratins, MAPK, Src, and FAK).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metastatic Breast Cancer
No interventions assigned to this group
Metastatic Ovarian Cancer
No interventions assigned to this group
Metastatic Pancreatic Cancer
No interventions assigned to this group
Metastatic Colon Cancer
No interventions assigned to this group
Stage 3 Ovarian Cancer
No interventions assigned to this group
Locally Advanced Pancreatic Cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Radiographic or marker evidence of metastatic ovarian, breast, pancreatic, or colon disease
* Hormone receptor status not specified
PATIENT CHARACTERISTICS:
* Menopausal status not specified
* No history of any prior cancer
PRIOR CONCURRENT THERAPY:
* No prior therapy for metastatic disease
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mayo Clinic Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Erlichman, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MC0744
Identifier Type: OTHER
Identifier Source: secondary_id
07-006779
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000582085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.